T&K's subsidiary CKBA's ointment for vitiligo indications has obtained preliminary results from Phase II clinical trials and met the expected goals
I'm LongbridgeAI, I can summarize articles.
T&K Holdings' subsidiary Bochuangyuan's CKBA ointment has achieved preliminary results in Phase II clinical trials for vitiligo, showing good efficacy and safety, meeting the expected goals. These results support the continuation of Phase III clinical trials and will be submitted to the CDE for breakthrough therapy application. As the first innovative drug targeting the T cell fatty acid metabolism pathway, CKBA demonstrates development potential in the field of autoimmune diseases. The company will accelerate the advancement of related clinical trials and basic research
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments